Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell(Hospital of the University of Pennsylvania), Thomas F. Gajewski(University of Chicago)
Cited by 382
Related Papers
Impact of oncogenic pathways on evasion of antitumour immune responses
|Nature reviews. Cancer|2018|652
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594